Daily BriefsECM

Daily Brief ECM: PT Global Digital Trade (BliBli) Pre-IPO – The Positives – Wide Offering and more

In today’s briefing:

  • PT Global Digital Trade (BliBli) Pre-IPO – The Positives – Wide Offering, Strong COVID Bounce Back
  • Blibli IPO – Indonesia E-Commerce Is Struggling, Blibli Even More So
  • Blibli IPO: The Bear Case
  • Giant Biogene Pre-IPO – Thoughts on Valuation

PT Global Digital Trade (BliBli) Pre-IPO – The Positives – Wide Offering, Strong COVID Bounce Back

By Sumeet Singh

  • PT Global Digital Trade (1437710D IJ)  (BliBli) aims to raise up to US$530m in its Indonesian IPO.
  • BliBli provides e-commerce services across Indonesia to both retail consumers and institutions
  • In this note, we’ll talk about the positive aspects of the deal.

Blibli IPO – Indonesia E-Commerce Is Struggling, Blibli Even More So

By Oshadhi Kumarasiri

  • Blibli (1437710D IJ), one of Indonesia’s leading e-commerce platforms is looking to raise around $470-530m via an IPO on Indonesia Stock Exchange.
  • Looking at Shopee’s struggles in the past year and Bukalapak’s rapid fall following the IPO, we think investors are unlikely to be interested in the Blibli IPO.
  • This could mean that Blibli’s days are numbered as it is resting all hopes on the IPO to fund its short-term loan repayment obligations.

Blibli IPO: The Bear Case

By Arun George

  • Blibli (1437710D IJ), a leading Indonesian e-commerce player, has launched an IDR8.2 trillion (US$530 million) Indonesian IPO. Bookbuilding is from 17 to 24 October.
  • In Blibli IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.  
  • The key elements of the bear case rest on weak sector sentiment, an unclear path to profitability, and credible long-term funding to support the high cash burn.  

Giant Biogene Pre-IPO – Thoughts on Valuation

By Sumeet Singh

  • Giant Biogene Holding (GBH HK) aims to raise around US$500m in its Hong Kong IPO.
  • GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
  • We had looked at the company’s past performance and undertaken a peer comparison in our previous notes. In this note, we’ll talk about valuations.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars